Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV

Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial

(2021) Franco Maggiolo et al.   Infectious Diseases and Therapy

Polypharmacy and potential drug–drug interactions for people with HIV in the UK from the Climate‐HIV database

(2020) C Okoli et al.   HIV MEDICINE

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-Existing NRTI Resistance

(2020) Rima K. Acosta et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials

(2020) Chloe Orkin et al.   Lancet HIV

Substantial decline in heavily treated therapy-experienced persons with HIV with limited antiretroviral treatment options

(2020) Kristina L. Bajema et al.   AIDS

The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile

(2020) Nicola Squillace et al.   Drug Design Development and Therapy

Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment-Experienced Patients

(2020) Jason J Schafer et al.   Open Forum Infectious Diseases

Risk and Cost Associated With Drug–Drug Interactions Among Aging HIV Patients Receiving Combined Antiretroviral Therapy in France

(2019) Ludivine Demessine et al.   Open Forum Infectious Diseases

Lipid changes due to tenofovir alafenamide are reversible by switching back to tenofovir disoproxil fumarate

(2019) Ana Milinkovic et al.   AIDS

Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I

(2019) Kristen Andreatta et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate

(2019) Gregory D Huhn et al.   Open Forum Infectious Diseases

What did we learn from the bictegravir switch studies?

(2018) Marianne Harris   Lancet HIV

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

(2018) Jean-Michel Molina et al.   Lancet HIV

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial

(2018) Eric S Daar et al.   Lancet HIV

Polypharmacy and Risk of Antiretroviral Drug Interactions Among the Aging HIV-Infected Population

(2013) Carol Holtzman et al.   JOURNAL OF GENERAL INTERNAL MEDICINE